
1. nat microbiol. 2017 oct;2(10):1403-1414. doi: 10.1038/s41564-017-0007-4. epub
2017 aug 14.

hexahydroquinolines antimalarial candidates potent blood-stage and
transmission-blocking activity.

vanaerschot m(1), lucantoni l(2), li t(3), combrinck jm(4), ruecker a(5)(6)(7),
kumar trs(1), rubiano k(1), ferreira pe(8), siciliano g(9), gulati s(1), henrich 
pp(1), ng cl(1), murithi jm(1), corey vc(10), duffy s(2), lieberman oj(1), veiga 
mi(8), sinden re(5), alano p(9), delves mj(5), lee sim k(3), winzeler ea(10),
egan tj(11), hoffman sl(3), avery vm(2), fidock da(12)(13).

author information: 
(1)department microbiology immunology, columbia university medical center,
new york, ny, 10032, usa.
(2)discovery biology, griffith institute drug discovery, griffith university,
nathan, 4111, queensland, australia.
(3)sanaria inc., rockville, md, 20852, usa.
(4)division pharmacology, department medicine, university cape town,
cape town, 7925, south africa.
(5)department life sciences, imperial college, london, sw7 2az, uk.
(6)mahidol-oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, 10400, thailand.
(7)centre tropical medicine global health, nuffield department of
medicine, university oxford, oxford, ox3 7fz, uk.
(8)life health sciences research institute (icvs), school medicine,
university minho, 4710-057, braga, portugal.
(9)dipartimento di malattie infettive, parassitarie ed immunomediate, istituto
superiore di sanità, 00161, rome, italy.
(10)university california, san diego, school medicine, la jolla, ca, 92093,
usa.
(11)department chemistry, university cape town, cape town, 7700, south
africa.
(12)department microbiology immunology, columbia university medical
center, new york, ny, 10032, usa. df2260@cumc.columbia.edu.
(13)division infectious diseases, department medicine, columbia university 
medical center, new york, ny, 10032, usa. df2260@cumc.columbia.edu.

comment in
    nat microbiol. 2017 oct;2(10):1336-1337.

antimalarial compounds dual therapeutic transmission-blocking activity
are desired high-value partners combination therapies. here, report the
identification characterization hexahydroquinolines (hhqs) show low
nanomolar potency pathogenic transmissible intra-erythrocytic
forms malaria parasite plasmodium falciparum. activity translates
into potent transmission-blocking potential, shown vitro male gamete
formation assays reduced oocyst infection prevalence anopheles
mosquitoes. vivo studies illustrated ability lead hhqs suppress
plasmodium berghei blood-stage parasite proliferation. resistance selection
studies, confirmed crispr-cas9-based gene editing, identified digestive
vacuole membrane-spanning transporter pfmdr1 (p. falciparum multidrug resistance 
gene-1) as determinant parasite resistance hhqs. haemoglobin haem
fractionation assays suggest mode action results reduced haemozoin
levels might involve inhibition host haemoglobin uptake into
intra-erythrocytic parasites. furthermore, parasites resistant hhqs displayed 
increased susceptibility several first-line antimalarial drugs, including
lumefantrine, confirming hhqs different mode action other
antimalarials drugs pfmdr1 known confer resistance. work
evokes therapeutic strategies combine opposing selective pressures this
parasite transporter approach countering emergence transmission 
of multidrug-resistant p. falciparum malaria.

doi: 10.1038/s41564-017-0007-4 
pmcid: pmc5708124
pmid: 28808258  [indexed medline]

